Michael Farrell, Jeyran Shahbazi, Mark Chambers, Marianne Byrne, Jaleh Gholami, Emma Zahra, Jason Grebely, Nicholas Lintzeris, Briony Larance, Robert Ali, Suzanne Nielsen, Adrian Dunlop, Gregory J Dore, Michael McDonough, Mark Montebello, Rob Weiss, Craig Rodgers, Jon Cook, Louisa Degenhardt
BACKGROUND: The most recent formulation of buprenorphine treatment is extended-release depot injections (BUP-XR) that are administered subcutaneously by health care professionals. This study aimed to observe treatment outcomes of BUP-XR delivered in standard practice during a 96-week follow-up period in a community setting. METHODS: This study is an extension of the CoLAB study, a prospective single-arm, multicentre, open label trial (N=100, 7 sites in Australia) among people with opioid dependence who received monthly injections of BUP-XR to evaluate the retention in treatment...
March 23, 2024: International Journal on Drug Policy